CD 49d ( ITGA 4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status
We investigated CD 49d (also termed ITGA 4) expression and its biological and clinical correlations in 415 patients with chronic lymphocytic leukaemia. CD 49d expression was stable over the course of the disease. A high expression of CD 49d (>30%) was found in 142/415 (34%) patients and was assoc...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2016-01, Vol.172 (1), p.48-55 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 55 |
|---|---|
| container_issue | 1 |
| container_start_page | 48 |
| container_title | British journal of haematology |
| container_volume | 172 |
| creator | Baumann, Tycho Delgado, Julio Santacruz, Rodrigo Martínez‐Trillos, Alejandra Rozman, María Aymerich, Marta López, Cristina Costa, Dolors Carrió, Anna Villamor, Neus Montserrat, Emili |
| description | We investigated
CD
49d (also termed
ITGA
4) expression and its biological and clinical correlations in 415 patients with chronic lymphocytic leukaemia.
CD
49d expression was stable over the course of the disease. A high expression of
CD
49d (>30%) was found in 142/415 (34%) patients and was associated with progressive disease (advanced clinical stage, high serum lactate dehydrogenase or β
2
‐microglobulin levels; all
p
<
0·05) and aggressive disease biology (increased
ZAP
70 or
CD
38, unmutated
IGHV
, trisomy 12, mutations of
NOTCH
1
and
SF
3B1
; all
P
<
0·05). A higher
CD
49d expression was also associated with a lower blood lymphocyte count and a higher number of lymphoid areas involved by the disease. Patients with high
CD
49d expression were treated more frequently (55% vs. 27%;
P
<
0·001) and earlier (median time to treatment [
TTT
] 65·4 months vs. not reached;
P
<
0·001) than those with low
CD
49d expression. However, no significant differences in response rates were observed. In the subgroup of patients with mutated
IGHV
, high
CD
49d expression was predictive of a shorter
TTT
while other markers, such as
ZAP
70 and
CD
38, were not. In conclusion, in this study
CD
49d expression correlated with high‐risk
CLL
biomarkers and proved to be useful for separating patients with mutated
IGHV
into two different prognostic groups. |
| doi_str_mv | 10.1111/bjh.13788 |
| format | Article |
| fullrecord | <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1111_bjh_13788</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1111_bjh_13788</sourcerecordid><originalsourceid>FETCH-LOGICAL-c748-3ac1d90dda55ae503cdca4d58c0a20bf6fdfb51b93c60c5507e88527f4d16d2c3</originalsourceid><addsrcrecordid>eNotkLtOwzAYhS0EEuUy8Ab_SIeU37GdpGNVoK1UiaVijRxfFJcmjmxX0HfgoUmBs5zvLGf4CHmgOKNjnpp9O6OsrKoLMqGsEFlOOb0kE0QsM4q8uiY3Me4RKUNBJ-R7-Qx8ruERNrvVAvgUzNcQTIzO9-AiSBiXdir5AN5Ccp2B5MG6EBOkYGTqTJ_A9TDI5EaM8OlSC6oNvncKDqduaL06pTOb44c0nZMgew3dMclkNGxW63eIIx_jHbmy8hDN_X_fkt3ry265zrZvq81ysc1UyauMSUX1HLWWQkgjkCmtJNeiUihzbGxhtW0EbeZMFaiEwNJUlchLyzUtdK7YLZn-3argYwzG1kNwnQynmmJ9tliPFutfi-wH6j1mjQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>CD 49d ( ITGA 4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status</title><source>Wiley Free Content</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Baumann, Tycho ; Delgado, Julio ; Santacruz, Rodrigo ; Martínez‐Trillos, Alejandra ; Rozman, María ; Aymerich, Marta ; López, Cristina ; Costa, Dolors ; Carrió, Anna ; Villamor, Neus ; Montserrat, Emili</creator><creatorcontrib>Baumann, Tycho ; Delgado, Julio ; Santacruz, Rodrigo ; Martínez‐Trillos, Alejandra ; Rozman, María ; Aymerich, Marta ; López, Cristina ; Costa, Dolors ; Carrió, Anna ; Villamor, Neus ; Montserrat, Emili</creatorcontrib><description>We investigated
CD
49d (also termed
ITGA
4) expression and its biological and clinical correlations in 415 patients with chronic lymphocytic leukaemia.
CD
49d expression was stable over the course of the disease. A high expression of
CD
49d (>30%) was found in 142/415 (34%) patients and was associated with progressive disease (advanced clinical stage, high serum lactate dehydrogenase or β
2
‐microglobulin levels; all
p
<
0·05) and aggressive disease biology (increased
ZAP
70 or
CD
38, unmutated
IGHV
, trisomy 12, mutations of
NOTCH
1
and
SF
3B1
; all
P
<
0·05). A higher
CD
49d expression was also associated with a lower blood lymphocyte count and a higher number of lymphoid areas involved by the disease. Patients with high
CD
49d expression were treated more frequently (55% vs. 27%;
P
<
0·001) and earlier (median time to treatment [
TTT
] 65·4 months vs. not reached;
P
<
0·001) than those with low
CD
49d expression. However, no significant differences in response rates were observed. In the subgroup of patients with mutated
IGHV
, high
CD
49d expression was predictive of a shorter
TTT
while other markers, such as
ZAP
70 and
CD
38, were not. In conclusion, in this study
CD
49d expression correlated with high‐risk
CLL
biomarkers and proved to be useful for separating patients with mutated
IGHV
into two different prognostic groups.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.13788</identifier><language>eng</language><ispartof>British journal of haematology, 2016-01, Vol.172 (1), p.48-55</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c748-3ac1d90dda55ae503cdca4d58c0a20bf6fdfb51b93c60c5507e88527f4d16d2c3</citedby><cites>FETCH-LOGICAL-c748-3ac1d90dda55ae503cdca4d58c0a20bf6fdfb51b93c60c5507e88527f4d16d2c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Baumann, Tycho</creatorcontrib><creatorcontrib>Delgado, Julio</creatorcontrib><creatorcontrib>Santacruz, Rodrigo</creatorcontrib><creatorcontrib>Martínez‐Trillos, Alejandra</creatorcontrib><creatorcontrib>Rozman, María</creatorcontrib><creatorcontrib>Aymerich, Marta</creatorcontrib><creatorcontrib>López, Cristina</creatorcontrib><creatorcontrib>Costa, Dolors</creatorcontrib><creatorcontrib>Carrió, Anna</creatorcontrib><creatorcontrib>Villamor, Neus</creatorcontrib><creatorcontrib>Montserrat, Emili</creatorcontrib><title>CD 49d ( ITGA 4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status</title><title>British journal of haematology</title><description>We investigated
CD
49d (also termed
ITGA
4) expression and its biological and clinical correlations in 415 patients with chronic lymphocytic leukaemia.
CD
49d expression was stable over the course of the disease. A high expression of
CD
49d (>30%) was found in 142/415 (34%) patients and was associated with progressive disease (advanced clinical stage, high serum lactate dehydrogenase or β
2
‐microglobulin levels; all
p
<
0·05) and aggressive disease biology (increased
ZAP
70 or
CD
38, unmutated
IGHV
, trisomy 12, mutations of
NOTCH
1
and
SF
3B1
; all
P
<
0·05). A higher
CD
49d expression was also associated with a lower blood lymphocyte count and a higher number of lymphoid areas involved by the disease. Patients with high
CD
49d expression were treated more frequently (55% vs. 27%;
P
<
0·001) and earlier (median time to treatment [
TTT
] 65·4 months vs. not reached;
P
<
0·001) than those with low
CD
49d expression. However, no significant differences in response rates were observed. In the subgroup of patients with mutated
IGHV
, high
CD
49d expression was predictive of a shorter
TTT
while other markers, such as
ZAP
70 and
CD
38, were not. In conclusion, in this study
CD
49d expression correlated with high‐risk
CLL
biomarkers and proved to be useful for separating patients with mutated
IGHV
into two different prognostic groups.</description><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNotkLtOwzAYhS0EEuUy8Ab_SIeU37GdpGNVoK1UiaVijRxfFJcmjmxX0HfgoUmBs5zvLGf4CHmgOKNjnpp9O6OsrKoLMqGsEFlOOb0kE0QsM4q8uiY3Me4RKUNBJ-R7-Qx8ruERNrvVAvgUzNcQTIzO9-AiSBiXdir5AN5Ccp2B5MG6EBOkYGTqTJ_A9TDI5EaM8OlSC6oNvncKDqduaL06pTOb44c0nZMgew3dMclkNGxW63eIIx_jHbmy8hDN_X_fkt3ry265zrZvq81ysc1UyauMSUX1HLWWQkgjkCmtJNeiUihzbGxhtW0EbeZMFaiEwNJUlchLyzUtdK7YLZn-3argYwzG1kNwnQynmmJ9tliPFutfi-wH6j1mjQ</recordid><startdate>201601</startdate><enddate>201601</enddate><creator>Baumann, Tycho</creator><creator>Delgado, Julio</creator><creator>Santacruz, Rodrigo</creator><creator>Martínez‐Trillos, Alejandra</creator><creator>Rozman, María</creator><creator>Aymerich, Marta</creator><creator>López, Cristina</creator><creator>Costa, Dolors</creator><creator>Carrió, Anna</creator><creator>Villamor, Neus</creator><creator>Montserrat, Emili</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201601</creationdate><title>CD 49d ( ITGA 4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status</title><author>Baumann, Tycho ; Delgado, Julio ; Santacruz, Rodrigo ; Martínez‐Trillos, Alejandra ; Rozman, María ; Aymerich, Marta ; López, Cristina ; Costa, Dolors ; Carrió, Anna ; Villamor, Neus ; Montserrat, Emili</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c748-3ac1d90dda55ae503cdca4d58c0a20bf6fdfb51b93c60c5507e88527f4d16d2c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Baumann, Tycho</creatorcontrib><creatorcontrib>Delgado, Julio</creatorcontrib><creatorcontrib>Santacruz, Rodrigo</creatorcontrib><creatorcontrib>Martínez‐Trillos, Alejandra</creatorcontrib><creatorcontrib>Rozman, María</creatorcontrib><creatorcontrib>Aymerich, Marta</creatorcontrib><creatorcontrib>López, Cristina</creatorcontrib><creatorcontrib>Costa, Dolors</creatorcontrib><creatorcontrib>Carrió, Anna</creatorcontrib><creatorcontrib>Villamor, Neus</creatorcontrib><creatorcontrib>Montserrat, Emili</creatorcontrib><collection>CrossRef</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Baumann, Tycho</au><au>Delgado, Julio</au><au>Santacruz, Rodrigo</au><au>Martínez‐Trillos, Alejandra</au><au>Rozman, María</au><au>Aymerich, Marta</au><au>López, Cristina</au><au>Costa, Dolors</au><au>Carrió, Anna</au><au>Villamor, Neus</au><au>Montserrat, Emili</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CD 49d ( ITGA 4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status</atitle><jtitle>British journal of haematology</jtitle><date>2016-01</date><risdate>2016</risdate><volume>172</volume><issue>1</issue><spage>48</spage><epage>55</epage><pages>48-55</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><abstract>We investigated
CD
49d (also termed
ITGA
4) expression and its biological and clinical correlations in 415 patients with chronic lymphocytic leukaemia.
CD
49d expression was stable over the course of the disease. A high expression of
CD
49d (>30%) was found in 142/415 (34%) patients and was associated with progressive disease (advanced clinical stage, high serum lactate dehydrogenase or β
2
‐microglobulin levels; all
p
<
0·05) and aggressive disease biology (increased
ZAP
70 or
CD
38, unmutated
IGHV
, trisomy 12, mutations of
NOTCH
1
and
SF
3B1
; all
P
<
0·05). A higher
CD
49d expression was also associated with a lower blood lymphocyte count and a higher number of lymphoid areas involved by the disease. Patients with high
CD
49d expression were treated more frequently (55% vs. 27%;
P
<
0·001) and earlier (median time to treatment [
TTT
] 65·4 months vs. not reached;
P
<
0·001) than those with low
CD
49d expression. However, no significant differences in response rates were observed. In the subgroup of patients with mutated
IGHV
, high
CD
49d expression was predictive of a shorter
TTT
while other markers, such as
ZAP
70 and
CD
38, were not. In conclusion, in this study
CD
49d expression correlated with high‐risk
CLL
biomarkers and proved to be useful for separating patients with mutated
IGHV
into two different prognostic groups.</abstract><doi>10.1111/bjh.13788</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2016-01, Vol.172 (1), p.48-55 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_crossref_primary_10_1111_bjh_13788 |
| source | Wiley Free Content; Wiley Online Library Journals Frontfile Complete |
| title | CD 49d ( ITGA 4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T15%3A51%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CD%2049d%20(%20ITGA%204)%20expression%20is%20a%20predictor%20of%20time%20to%20first%20treatment%20in%20patients%20with%20chronic%20lymphocytic%20leukaemia%20and%20mutated%20IGHV%20status&rft.jtitle=British%20journal%20of%20haematology&rft.au=Baumann,%20Tycho&rft.date=2016-01&rft.volume=172&rft.issue=1&rft.spage=48&rft.epage=55&rft.pages=48-55&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.13788&rft_dat=%3Ccrossref%3E10_1111_bjh_13788%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |